NCT03290950: Phase 2 - A Study of Daratumumab in Patients With NDMM wKRd-D - Manhattan Trial

MANHATTAN TRIAL

NCT03290950: Phase 2 - A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma

Dara-KRd

A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma

This is a study to test the safety and effectiveness of the study drug, daratumumab in combination with carfilzomib, lenalidomide and dexamethasone. The purpose of this study is to test whether giving daratumumab along with the other drugs (carfilzomib, lenalidomide and dexamethasone) is safe for patients.

Carfilzomib (Kyprolis)

Lenalidomide (Revlimid)

Dexamethasone (Decadron)

Daratumumab (Darzalex)

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborator